🔗 Share this article

While America continues making historic adjustments to its vaccine guidelines, one figure appears in a surprising turn: Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the pandemic and has focused upon potential fatalities after Covid immunization in her recent position at the FDA.

Proposed Overhauls to Childhood Immunization Program

Health officials had intended to announce major revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of step with a large portion of the global community with little proof for benefit. This reveal has been delayed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the office this calendar year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending some childhood immunization guidelines in the US to become more in line with Denmark, a society with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Qualifications

Høeg has little discernible track record in pharmaceutical research, oversight or administrative roles, which has been customary for past leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a major agency. She lacks background in drug approvals.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that prior appointees who led the center have had.”

CDER has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just pays attention on the innovative therapies, but the generic program authorizes thousands of generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and each of these must be looked after,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership element to the position, which supervises over 5,000 employees. “It’s a huge leadership role, if you perform it correctly,” she added.

Agency Reaction and Contentious Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary said that the “inquiries are based on incorrect presumptions”.

“Her experience is consistent with the duties of her role,” the official explained, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a controversial one-day drug-approval program that apparently worried her former heads. “By what process are these therapies being picked for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards more relaxed rules of pharmaceuticals, with the exception of immunizations.”

Documented History on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if troubling, history, critics observe. She published a research paper using non-validated volunteer-provided data to assess the rate of heart inflammation following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are riskier than they are.

Part of her “desired changes” for the current government featured altering rules for novel immunizations and ending “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Høeg has reportedly suggested preventing adolescent males from getting Covid vaccines.

“She’s an thorough dogmatist who begins with her conclusions and works backwards to fit the evidence in a extremely disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|